Search results
Study identifies immunity threshold for protection against COVID-19 in children
Medical Xpress· 2 days agoAll participants received two doses of 10mcg Pfizer/BioNTech mRNA COVID-19 vaccination, 21 days apart. The team followed up with the participants for one year, during which ...
The images that show the two sides of AstraZeneca’s vaccine ‘miracle’
Daily Telegraph· 2 days agoAstraZeneca had been unable to identify the cause of the clots and the Government bought its Covid...
The images that show the two sides of AstraZeneca’s vaccine ‘miracle’
The Telegraph via Yahoo Finance· 2 days agoJamie Scott is nothing if not a fighter. He must be to have survived a reaction to his Covid-19...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 7 days agoIn 2020, the industry was thrust into the pandemic limelight as Pfizer and its partner BioNTech,...
Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound
BioPharma Dive via Yahoo Finance· 2 days agoLarge and small drugmakers are vying for a piece of what analysts view as one of the biggest market...
Biodexa gains license for polyposis asset as stock more than doubles
Pharmaceutical Technology via Yahoo Finance· 3 days agoIn the trial, thirty patients with FAP who are undergoing endoscopic surveillance will be given...
Unable to work since COVID vaccination, Gatineau man pins hopes on compensation
CBC via Yahoo News· 3 days agoA Gatineau, Que., man who developed a debilitating skin ailment after receiving a COVID-19 vaccine...
We May Be Facing an Epidemic of This Brain Disease
Mercola· 3 days agoAccording to mounting data, one of the more serious side effects of the COVID mRNA jabs appears to be dementia, and worse yet, this previously untransmissible disease may now be “contagious, ...
CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 days agoCureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript April 24, 2024 CureVac N.V. isn’t one of...
Eli Lilly assures investors it can overcome the high-quality problem of too much demand
CNBC· 2 days agoEli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly ...